Literature DB >> 10893322

Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women.

W Wang1, A Basinger, R A Neese, M Christiansen, M K Hellerstein.   

Abstract

Chronic nicotinic acid (NA) ingestion effectively lowers lipid levels, but adverse effects on glucose metabolism have been reported. Our goal was to investigate acute and chronic effects of NA on lipolysis and glucose metabolism in women. Healthy normolipidemic volunteers (n = 5) were studied twice; four-day hospital stays were separated by 1 mo, during which time subjects took increasing doses of NA to 2 g/day (500 mg, 4 times). In the second study, 500 mg of NA was given at 0800. Rates of appearance (R(a)) of free fatty acid (FFA), glycerol, and glucose were determined by isotope dilution (of [1,2,3,4-(13)C(4)]palmitate, [2-(13)C(1)]glycerol, and [U-(13)C(6)]glucose). Mass isotopomer distribution analysis was used to measure gluconeogenesis and glycogenolysis. Fasting FFA concentrations ([FFA]), R(a) FFA, and R(a) glycerol were nonsignificantly elevated after 1 mo. Acute NA induced a significant reduction followed by a rebound overshoot of [FFA], R(a) FFA, and R(a) glycerol. Whole body fat oxidation fell initially and then increased back to basal levels; endogenous glucose production (EGP) increased in parallel with carbohydrate oxidation and then returned to basal values. The increased EGP was due entirely to increased glycogenolysis, not gluconeogenesis. We conclude that chronic effects of NA on FFA metabolism are complex (acute suppression followed by overshoot of R(a) FFA and [FFA] on top of a trend toward basal elevations), that responses after NA are consistent with operation of a glucose-fatty acid cycle in peripheral tissues, and that secondary effects on EGP were through changes in glycogenolysis, not gluconeogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10893322     DOI: 10.1152/ajpendo.2000.279.1.E50

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  17 in total

Review 1.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug.

Authors:  Insug Kang; Sang-Wook Kim; Jang H Youn
Journal:  J Clin Endocrinol Metab       Date:  2011-08-03       Impact factor: 5.958

3.  Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats[S].

Authors:  Tobias Kroon; Tania Baccega; Arne Olsén; Johan Gabrielsson; Nicholas D Oakes
Journal:  J Lipid Res       Date:  2016-11-15       Impact factor: 5.922

Review 4.  Niacin in cardiovascular disease: recent preclinical and clinical developments.

Authors:  Janet E Digby; Neil Ruparelia; Robin P Choudhury
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-12-29       Impact factor: 8.311

5.  Protocol for the measurement of fatty acid and glycerol turnover in vivo in baboons.

Authors:  Raul A Bastarrachea; Sonya M Veron; Vidya Vaidyanathan; Maggie Garcia-Forey; V Saroja Voruganti; Paul B Higgins; Elizabeth J Parks
Journal:  J Lipid Res       Date:  2011-03-17       Impact factor: 5.922

6.  Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.

Authors:  Elisa Fabbrini; B Selma Mohammed; Kevin M Korenblat; Faidon Magkos; Jennifer McCrea; Bruce W Patterson; Samuel Klein
Journal:  J Clin Endocrinol Metab       Date:  2010-04-06       Impact factor: 5.958

7.  GPR120 suppresses adipose tissue lipolysis and synergizes with GPR40 in antidiabetic efficacy.

Authors:  Santhosh Satapati; Ying Qian; Margaret S Wu; Aleksandr Petrov; Ge Dai; Sheng-Ping Wang; Yonghua Zhu; Xiaolan Shen; Eric S Muise; Ying Chen; Emanuel Zycband; Adam Weinglass; Jerry Di Salvo; John S Debenham; Jason M Cox; Ping Lan; Vinit Shah; Stephen F Previs; Mark Erion; David E Kelley; Liangsu Wang; Andrew D Howard; Jin Shang
Journal:  J Lipid Res       Date:  2017-06-05       Impact factor: 5.922

Review 8.  Does nicotinic acid (niacin) lower blood pressure?

Authors:  H E Bays; D J Rader
Journal:  Int J Clin Pract       Date:  2008-11-28       Impact factor: 2.503

9.  Relationship between Changes in Plasma Adiponectin Concentration and Insulin Sensitivity after Niacin Therapy.

Authors:  Gemma Fraterrigo; Elisa Fabbrini; Bettina Mittendorfer; Stephen O'Rahilly; Philipp E Scherer; Bruce W Patterson; Samuel Klein
Journal:  Cardiorenal Med       Date:  2012-07-18       Impact factor: 2.041

10.  Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B.

Authors:  Mattijs M Heemskerk; Sjoerd A A van den Berg; Amanda C M Pronk; Jan-Bert van Klinken; Mariëtte R Boon; Louis M Havekes; Patrick C N Rensen; Ko Willems van Dijk; Vanessa van Harmelen
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-01-28       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.